Drugs / Adipose Derived Stem Cell (ADSC) Therapy
Adipose Derived Stem Cell (ADSC) Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02216630 | Aug 2014 → Jul 2017 | chronic obstructive pulmonary disease | Kimera Society Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose Derived Stem Cell (ADSC) Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02216630 ↗ |
| Modality | Cell therapy | “adipose derived stem cells (ASC) constitute an autologous cell product” NCT02216630 ↗ |
| Route | Intravenous | “The ADSCs are then isolated and injected intravenously.” NCT02216630 ↗ |